Abzena, a global CDMO specialising in complex biologics and bioconjugates, has introduced its enhanced mammalian cell line development platform, AbZelectPRO, as a standard offering for all customers. The platform now significantly reduces development timelines by more than 30%, enabling biopharma
Angiex, a biopharmaceutical company focused on developing innovative therapies for solid cancers, has begun patient dosing for its Phase 1 clinical trial of AGX101, a TM4SF1-directed Antibody-Drug Conjugate (ADC). The trial, which marks the first-in-human study for AGX101, is supported
Abzena, an end-to-end integrated contract development and manufacturing organization (CDMO) for complex biologics and bioconjugates, has teamed up with Argonaut Manufacturing Services, Inc., a cGMP CDMO serving the biopharmaceutical and diagnostics industries. The strategic partnership aims to provide a fully
Abzena an end-to-end integrated CDMO for complex biologics and bioconjugates has launched EpiScreen 2.0, an enhanced bioassay platform for predicting and evaluating immunogenicity risks in preclinical protein, antibody, and gene therapy therapeutics. The platform offers sensitive, multi-parametric, and data-rich assessments,
Abzena, a CDMO specialising in complex biologics and bioconjugates, has unveiled a significant expansion at its Bristol, PA bioconjugate development and cGMP manufacturing site. The expansion includes increased laboratory space, new equipment acquisitions, and upgrades to the existing facility. As
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
